Submission Type
Poster
Start Date
4-22-2020
Abstract
Epigenetic modifiers, like the DNA methylation inhibitor 5-Azacytidine (5-AzaC), have been shown to increase human leukocyte antigen (HLA) expression. The expression of HLA is required for a T-cell response to detect tumor cells. A lack of HLA expression allows tumor cells to escape immune detection. It has been previously shown that 5-AzaC is able to upregulate HLA-ABC expression in the cell line MDA-MB-435. However, other HLA proteins like HLA-E and HLA-G may be concurrently upregulated, which would have negative implications on tumor immunity. One flask of MDA-MB-435 cells was treated for 48 hours with 5-AzaC at 0.0025 mg/mL and another was left untreated. The cells were harvested and incubated with control antibodies or the experimental antibodies, Anti-HLA-ABC, Anti-HLA-G, and Anti-HLA-E and analyzed via flow cytometry. Preliminary experiments testing for the expression of HLA-E and HLA-G have both demonstrated a slight increase in their expression compared to the untreated cells. Although minor, the increase in HLA-E and HLA-G expression may have negative implications on tumor survival and pathogenesis. Understanding individual HLA upregulation may prove to be beneficial and applicable to cancer immunotherapy, an expanding field of improved cancer treatments.
Recommended Citation
Hansen, Adam and O'Donnell, Robert W., "493— The Effects of 5-Azacytidine on HLA-ABC, HLA-E, HLA-G and HLA-A Expression" (2020). GREAT Day Posters. 112.
https://knightscholar.geneseo.edu/great-day-symposium/great-day-2020/posters-2020/112
Included in
493— The Effects of 5-Azacytidine on HLA-ABC, HLA-E, HLA-G and HLA-A Expression
Epigenetic modifiers, like the DNA methylation inhibitor 5-Azacytidine (5-AzaC), have been shown to increase human leukocyte antigen (HLA) expression. The expression of HLA is required for a T-cell response to detect tumor cells. A lack of HLA expression allows tumor cells to escape immune detection. It has been previously shown that 5-AzaC is able to upregulate HLA-ABC expression in the cell line MDA-MB-435. However, other HLA proteins like HLA-E and HLA-G may be concurrently upregulated, which would have negative implications on tumor immunity. One flask of MDA-MB-435 cells was treated for 48 hours with 5-AzaC at 0.0025 mg/mL and another was left untreated. The cells were harvested and incubated with control antibodies or the experimental antibodies, Anti-HLA-ABC, Anti-HLA-G, and Anti-HLA-E and analyzed via flow cytometry. Preliminary experiments testing for the expression of HLA-E and HLA-G have both demonstrated a slight increase in their expression compared to the untreated cells. Although minor, the increase in HLA-E and HLA-G expression may have negative implications on tumor survival and pathogenesis. Understanding individual HLA upregulation may prove to be beneficial and applicable to cancer immunotherapy, an expanding field of improved cancer treatments.
Comments
Sponsored by Robert O'Donnell